MHP – THE VALUE OF REAL WORLD EVIDENCE FOR GPS

METHODOLOGY NOTE

ComRes interviewed 1,003 UK-based GPs online between 12th and 21st August 2015. Quotas were set to ensure a representative spread of GPs across the former SHA regions of England, Scotland, Wales and Northern Ireland. ComRes is a member of the British Polling Council and abides by its rules. All press releases or other publications must be checked with ComRes before use. ComRes requires 48 hours to check a press release unless otherwise agreed.

To commission a voting intention poll or a public opinion survey please contact Katharine Peacock: katharine.peacock@comres.co.uk

To register for Pollwatch, a monthly newsletter update on the polls, please email: pollwatch@comres.co.uk

Importance of evidence in your adoption of new treatments

ONLINE Fieldwork Dates: 12th-21st August 2015

Table 1

Absolutes/col percents

Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents
Summary table

	Ranking						Top 3	Mean
	Ranked 1st	Ranked 2nd	Ranked 3rd	Ranked 4th	Ranked 5th	Not ranked	Ranked in Top 3	Mean ranking
Base	1003	1003	1003	1003	1003	1003	1003	1003
How to best fit the treatment into the current protocol, including when to switch patients	298	232	177	132	128	36	707	1003
	30%	23%	18%	13%	13%	4%	70%	3.33
That use in clinical settings validates the phase 3 trial data	275	175	143	152	210	48	593	1003
	27%	17%	14%	15%	21%	5%	59%	3.01
How the treatment is being used by my peers in a clinical setting	250	246	189	150	126	42	685	1003
	25%	25%	19%	15%	13%	4%	68%	3.22
What the patient preference is for the treatment	93	148	220	239	262	41	461	1003
	9%	15%	22%	24%	26%	4%	46%	2.45
What the adherence rates are in a clinical setting	57	172	244	269	211	50	473	1003
	6%	17%	24%	27%	21%	5%	47%	2.45

COMRES

Importance of evidence in your adoption of new treatments
ONLINE Fieldwork Dates: 12th-21st August 2015

Table 2

Absolutes/col percents

Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents
1st (Region)

	Total		London		South East Coastal		South Central		South West		West Midlands		East Midlands		East of England		Yorkshire & Humber		North East		North West		Scotland		Wales		Northern Ireland		England		NHS London		NHS South of England		NHS Midlands and East SHA		NHS North of England	
Base	1003	100%	118	100%	60	100%	70	100%	90	100%	87	100%	71	100%	94	100%	85	100%	46	100%	114	100%	90	100%	50	100%	28	100%	835	100%	118	100%	220	100%	252	100%	245	100%
How to best fit the treatment into the current protocol, including when to switch patients																																						
Ranked 1st	298	30%	38	32%	18	30%	13	19%	20	22%	26	30%	27	38%	29	31%	26	31%	11	24%	39	34%	26	29%	14	28%	11	39%	247	30%	38	32%	51	23%	82	33%	76	31%
That use in clinical settings validates the phase 3 trial data																																						
Ranked 1st	275	27%	36	31%	11	18%	24	34%	30	33%	17	20%	10	14%	28	30%	24	28%	15	33%	28	25%	28	31%	18	36%	6	21%	223	27%	36	31%	65	30%	55	22%	67	27%
How the treatment is being used by my peers in a clinical setting																																						
Ranked 1st	250	25%	24	20%	14	23%	28	40%	23	26%	23	26%	21	30%	23	24%	19	22%	13	28%	28	25%	20	22%	8	16%	6	21%	216	26%	24	20%	65	30%	67	27%	60	24%
What the patient preference is for the treatment																																						
Ranked 1st	93	9%	10	8%	10	17%	4	6%	9	10%	9	10%	7	10%	7	7%	8	9%	0	0%	11	10%	9	10%	6	12%	3	11%	75	9%	10	8%	23	10%	23	9%	19	8%
What the adherence rates are in a clinical setting																																						
Ranked 1st	57	6%	7	6%	3	5%	0	0%	4	4%	9	10%	3	4%	7	7%	4	5%	5	11%	6	5%	3	3%	4	8%	2	7%	48	6%	7	6%	7	3%	19	8%	15	6%
Real world evidence is not useful to me	30	3%	3	3%	4	7%	1	1%	4	4%	3	3%	3	4%	0	0%	4	5%	2	4%	2	2%	4	4%	0	0%	0	0%	26	3%	3	3%	9	4%	6	2%	8	3%

Importance of evidence in your adoption of new treatments
ONLINE Fieldwork Dates: 12th-21st August 2015

Table 3

Absolutes/col percents

Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents
1st (GP info)

	Total		S2 - GP Type								D3 - Gender				D4 - Year of qualification								D6 - Age										D8 - CCG Involvement					
			GP Principal		Salaried GP		GP Registrar		Locum GP		Male		Female		1979 or earlier		1980-1989		1990-1999		2000-2010		Under 30		30 – 39		40 – 49		50 – 59		60 or over		I am, or plan to be, an active member of my CCG governing board		I am, or plan to be, a GP representative		I do not take an active part in my CCG	
Base	1003	100%	657	100%	225	100%	2	100%	119	100%	566	100%	437	100%	83	100%	239	100%	306	100%	375	100%	9	100%	354	100%	317	100%	248	100%	75	100%	90	100%	153	100%	595	100%
How to best fit the treatment into the current protocol, including when to switch patients																																						
Ranked 1st	298	30%	185	28%	75	33%	0	0%	38	32%	162	29%	136	31%	23	28%	71	30%	86	28%	118	31%	3	33%	113	32%	89	28%	73	29%	20	27%	20	22%	51	33%	177	30%
That use in clinical settings validates the phase 3 trial data																																						
Ranked 1st	275	27%	180	27%	60	27%	1	50%	34	29%	150	27%	125	29%	21	25%	78	33%	86	28%	90	24%	3	33%	79	22%	92	29%	79	32%	22	29%	25	28%	38	25%	161	27%
How the treatment is being used by my peers in a clinical setting																																						
Ranked 1st	250	25%	171	26%	51	23%	1	50%	27	23%	142	25%	108	25%	17	20%	59	25%	82	27%	92	25%	1	11%	85	24%	89	28%	58	23%	17	23%	24	27%	31	20%	161	27%
What the patient preference is for the treatment																																						
Ranked 1st	93	9%	60	9%	21	9%	0	0%	12	10%	62	11%	31	7%	13	16%	18	8%	24	8%	38	10%	1	11%	38	11%	23	7%	21	8%	10	13%	12	13%	13	9%	50	8%
What the adherence rates are in a clinical setting																																						
Ranked 1st	57	6%	42	6%	10	4%	0	0%	5	4%	35	6%	22	5%	8	10%	9	4%	18	6%	22	6%	1	11%	23	7%	16	5%	11	4%	6	8%	7	8%	13	9%	29	5%
Real world evidence is not useful to me																																						
	30	3%	19	3%	8	4%	0	0%	3	3%	15	3%	15	3%	1	1%	4	2%	10	3%	15	4%	0	0%	16	5%	8	3%	6	2%	0	0%	2	2%	7	5%	17	3%

COMRES

Importance of evidence in your adoption of new treatments
ONLINE Fieldwork Dates: 12th-21st August 2015

Table 4

Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents
1st (Practice info)

	Total		D2 - Practice Location									D1 - Overall practice size							D5 - Dispensing Practice				D7 - Number of patients on practice list								
			Rural area		Urban area		Semi-rural area		Suburban area		Other		1-2		3-5		6-10		11 or more		Yes		No		1-2500		2501-5000		5001-7500		7501-10000		10001+	
Base	1003	100%	94	100%	403	100%	235	100%	266	100%	5	100%	63	100%	413	100%	437	100%	90	100%	189	100%	814	100%	39	100%	158	100%	225	100%	231	100%	350	100%
How to best fit the treatment into the current protocol, including when to switch patients																																		
Ranked 1st	298	30%	28	30%	132	33%	64	27%	72	27%	2	40%	16	25%	115	28%	139	32%	28	31%	51	27%	247	30%	11	28%	47	30%	60	27%	68	29%	112	32%
That use in clinical settings validates the phase 3 trial data																																		
Ranked 1st	275	27%	23	24%	112	28%	65	28%	74	28%	1	20%	13	21%	128	31%	116	27%	18	20%	43	23%	232	29%	6	15%	48	30%	70	31%	66	29%	85	24%
How the treatment is being used by my peers in a clinical setting																																		
Ranked 1st	250	25%	25	27%	88	22%	68	29%	68	26%	1	20%	16	25%	95	23%	113	26%	26	29%	61	32%	189	23%	11	28%	39	25%	54	24%	62	27%	84	24%
What the patient preference is for the treatment																																		
Ranked 1st	93	9%	10	11%	38	9%	22	9%	22	8%	1	20%	11	17%	36	9%	38	9%	8	9%	18	10%	75	9%	7	18%	9	6%	20	9%	22	10%	35	10%
What the adherence rates are in a clinical setting																																		
Ranked 1st	57	6%	6	6%	22	5%	11	5%	18	7%	0	0%	3	5%	27	7%	20	5%	7	8%	12	6%	45	6%	2	5%	8	5%	14	6%	7	3%	26	7%
Real world evidence is not useful to me	30	3%	2	2%	11	3%	5	2%	12	5%	0	0%	4	6%	12	3%	11	3%	3	3%	4	2%	26	3%	2	5%	7	4%	7	3%	6	3%	8	2%

COMRES

Importance of evidence in your adoption of new treatments
ONLINE Fieldwork Dates: 12th-21st August 2015

Table 5

Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents
Top 3 (Region)

	Total		London		South East Coastal		South Central		South West		West Midlands		East Midlands		East of England		Yorkshire & Humber		North East		North West		Scotland		Wales		Northern Ireland		England		NHS London		NHS South of England		NHS Midlands and East SHA		NHS North of England	
Base	1003	100%	118	100%	60	100%	70	100%	90	100%	87	100%	71	100%	94	100%	85	100%	46	100%	114	100%	90	100%	50	100%	28	100%	835	100%	118	100%	220	100%	252	100%	245	100%
How to best fit the treatment into the current protocol, including when to switch patients																																						
Ranked in Top 3	707	70%	80	68%	43	72%	41	59%	63	70%	61	70%	56	79%	74	79%	59	69%	23	50%	86	75%	66	73%	36	72%	19	68%	586	70%	80	68%	147	67%	191	76%	168	69%
How the treatment is being used by my peers in a clinical setting																																						
Ranked in Top 3	685	68%	84	71%	35	58%	57	81%	55	61%	63	72%	49	69%	64	68%	55	65%	29	63%	81	71%	64	71%	29	58%	20	71%	572	69%	84	71%	147	67%	176	70%	165	67%
That use in clinical settings validates the phase 3 trial data																																						
Ranked in Top 3	593	59%	70	59%	27	45%	46	66%	57	63%	44	51%	40	56%	58	62%	58	68%	29	63%	61	54%	53	59%	29	58%	21	75%	490	59%	70	59%	130	59%	142	56%	148	60%
What the adherence rates are in a clinical setting																																						
Ranked in Top 3	473	47%	58	49%	35	58%	29	41%	44	49%	38	44%	36	51%	44	47%	35	41%	25	54%	52	46%	35	39%	31	62%	11	39%	396	47%	58	49%	108	49%	118	47%	112	46%
What the patient preference is for the treatment																																						
Ranked in Top 3	461	46%	53	45%	28	47%	34	49%	39	43%	46	53%	23	32%	42	45%	36	42%	26	57%	56	49%	40	44%	25	50%	13	46%	383	46%	53	45%	101	46%	111	44%	118	48%
Real world evidence is not useful to me	30	3%	3	3%	4	7%	1	1%	4	4%	3	3%	3	4%	0	0%	4	5%	2	4%	2	2%	4	4%	0	0%	0	0%	26	3%	3	3%	9	4%	6	2%	8	3%

COMRES

Importance of evidence in your adoption of new treatments
ONLINE Fieldwork Dates: 12th-21st August 2015

Table 6

Absolutes/col percents

Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents

Top 3 (GP info)

	Total		S2 - GP Type								D3 - Gender				D4 - Year of qualification								D6 - Age										D8 - CCG Involvement					
			GP Principal		Salaried GP		GP Registrar		Locum GP		Male		Female		1979 or earlier		1980-1989		1990-1999		2000-2010		Under 30		30 – 39		40 – 49		50 – 59		60 or over		I am, or plan to be, an active member of my CCG governing board		I am, or plan to be, a GP representative		I do not take an active part in my CCG	
Base	1003	100%	657	100%	225	100%	2	100%	119	100%	566	100%	437	100%	83	100%	239	100%	306	100%	375	100%	9	100%	354	100%	317	100%	248	100%	75	100%	90	100%	153	100%	595	100%
How to best fit the treatment into the current protocol, including when to switch patients																																							
Ranked in Top 3	707	70%	463	70%	154	68%	1	50%	89	75%	396	70%	311	71%	55	66%	173	72%	214	70%	265	71%	7	78%	249	70%	221	70%	177	71%	53	71%	59	66%	108	71%	421	71%
How the treatment is being used by my peers in a clinical setting																																							
Ranked in Top 3	685	68%	449	68%	156	69%	1	50%	79	66%	377	67%	308	70%	52	63%	165	69%	215	70%	253	67%	5	56%	238	67%	228	72%	165	67%	49	65%	60	67%	97	63%	417	70%
That use in clinical settings validates the phase 3 trial data																																							
Ranked in Top 3	593	59%	401	61%	121	54%	1	50%	70	59%	344	61%	249	57%	49	59%	161	67%	176	58%	207	55%	5	56%	191	54%	186	59%	162	65%	49	65%	56	62%	90	59%	346	58%
What the adherence rates are in a clinical setting																																							
Ranked in Top 3	473	47%	313	48%	107	48%	1	50%	52	44%	276	49%	197	45%	48	58%	108	45%	149	49%	168	45%	4	44%	156	44%	153	48%	120	48%	40	53%	45	50%	73	48%	279	47%
What the patient preference is for the treatment																																							
Ranked in Top 3	461	46%	288	44%	113	50%	2	100%	58	49%	260	46%	201	46%	42	51%	98	41%	134	44%	187	50%	6	67%	180	51%	139	44%	102	41%	34	45%	44	49%	70	46%	271	46%
Real world evidence is not useful to me	30	3%	19	3%	8	4%	0	0%	3	3%	15	3%	15	3%	1	1%	4	2%	10	3%	15	4%	0	0%	16	5%	8	3%	6	2%	0	0%	2	2%	7	5%	17	3%

ComRes

Importance of evidence in your adoption of new treatments
ONLINE Fieldwork Dates: 12th-21st August 2015

Table 7

Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents
Top 3 (Practice info)

	Total		D2 - Practice Location									D1 - Overall practice size							D5 - Dispensing Practice				D7 - Number of patients on practice list								
			Rural area		Urban area		Semi-rural area		Suburban area		Other		1-2		3-5		6-10		11 or more		Yes		No		1-2500		2501-5000		5001-7500		7501-10000		10001+	
Base	1003	100%	94	100%	403	100%	235	100%	266	100%	5	100%	63	100%	413	100%	437	100%	90	100%	189	100%	814	100%	39	100%	158	100%	225	100%	231	100%	350	100%
How to best fit the treatment into the current protocol, including when to switch patients																																	
Ranked in Top 3	707	70%	71	76%	285	71%	169	72%	178	67%	4	80%	41	65%	281	68%	321	73%	64	71%	140	74%	567	70%	25	64%	112	71%	155	69%	167	72%	248	71%
How the treatment is being used by my peers in a clinical setting																																	
Ranked in Top 3	685	68%	66	70%	275	68%	160	68%	181	68%	3	60%	37	59%	276	67%	305	70%	67	74%	136	72%	549	67%	27	69%	111	70%	145	64%	155	67%	247	71%
That use in clinical settings validates the phase 3 trial data																																	
Ranked in Top 3	593	59%	58	62%	237	59%	138	59%	157	59%	3	60%	35	56%	245	59%	261	60%	52	58%	107	57%	486	60%	22	56%	97	61%	131	58%	139	60%	204	58%
What the adherence rates are in a clinical setting																																	
Ranked in Top 3	473	47%	39	41%	198	49%	104	44%	130	49%	2	40%	27	43%	211	51%	193	44%	42	47%	82	43%	391	48%	19	49%	63	40%	119	53%	107	46%	165	47%
What the patient preference is for the treatment																																	
Ranked in Top 3	461	46%	42	45%	181	45%	119	51%	116	44%	3	60%	37	59%	190	46%	198	45%	36	40%	90	48%	371	46%	18	46%	70	44%	104	46%	107	46%	162	46%
Real world evidence is not useful to me	30	3%	2	2%	11	3%	5	2%	12	5%	0	0%	4	6%	12	3%	11	3%	3	3%	4	2%	26	3%	2	5%	7	4%	7	3%	6	3%	8	2%

COMRES

Absolutes/col percents

Table 8
Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents

Columns: Total | London (A) | South East Coastal (B) | South Central (C) | South West (D) | West Midlands (E) | East Midlands (F) | East of England (G) | Yorkshire & Humber (H) | North East (I) | North West (J) | Scotland (K) | Wales (L) | Northern Ireland (M) [S3 - Region] | England (N) [S3 - England] | NHS London (O) | NHS South of England (P) | NHS Midlands and East SHA (Q) | NHS North of England (R) [S3 - England NHS Networks]

What the patient preference is for the treatment

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
Ranked 1st	93 9%	10 I8%	10 CI17%	4 I6%	9 I10%	9 I10%	7 I10%	7 I7%	8 I9%	0 0%	11 I10%	9 I10%	6 I12%	3 11%	75 9%	10 8%	23 10%	23 9%	19 8%
Ranked 2nd	148 15%	26 BFm22%	5 8%	9 13%	13 14%	11 13%	4 6%	13 14%	13 F15%	12 BFm26%	18 F16%	14 F16%	8 16%	2 7%	124 15%	26 PQ22%	27 12%	28 11%	43 Q18%
Ranked 3rd	220 22%	17 14%	13 22%	21 A30%	17 19%	26 AF30%	12 17%	22 23%	15 18%	14 A30%	27 24%	17 19%	11 22%	8 29%	184 22%	17 14%	51 O23%	60 O24%	56 O23%
Ranked 4th	239 24%	23 19%	11 18%	17 24%	22 24%	21 24%	18 25%	28 30%	27 A32%	9 20%	23 20%	21 23%	12 24%	7 25%	199 24%	23 19%	50 23%	67 27%	59 24%
Ranked 5th	262 26%	38 EHI32%	17 28%	17 24%	23 26%	17 20%	27 EHI38%	24 26%	17 20%	8 17%	31 27%	24 27%	13 26%	6 21%	219 26%	38 32%	57 26%	68 27%	56 23%
Not ranked	41 4%	4 GL3%	4 GL7%	2 3%	6 GL7%	3 3%	3 4%	0 0%	5 GL6%	3 7%	4 GL4%	5 GL6%	0 0%	2 7%	34 4%	4 3%	12 5%	6 2%	12 5%
Total	1003 100%	118 100%	60 100%	70 100%	90 100%	87 100%	71 100%	94 100%	85 100%	46 100%	114 100%	90 100%	50 100%	28 100%	835 100%	118 100%	220 100%	252 100%	245 100%

That use in clinical settings validates the phase 3 trial data

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
Ranked 1st	275 27%	36 F31%	11 18%	24 BEF34%	30 BEF33%	17 20%	10 14%	28 F30%	24 F28%	15 F33%	28 25%	28 F31%	18 BEF36%	6 21%	223 27%	36 31%	65 30%	55 22%	67 27%
Ranked 2nd	175 17%	19 16%	11 18%	13 19%	13 14%	14 16%	17 K24%	17 18%	20 K24%	8 17%	19 17%	10 11%	7 14%	7 25%	151 18%	19 16%	37 17%	48 19%	47 19%
Ranked 3rd	143 14%	15 13%	5 8%	9 13%	14 16%	13 15%	13 18%	13 14%	14 16%	6 13%	14 12%	15 17%	4 8%	8 bI29%	116 14%	15 13%	28 13%	39 15%	34 14%
Ranked 4th	152 15%	14 12%	15 AHm25%	10 14%	12 13%	15 m17%	15 m21%	16 m17%	9 11%	8 m17%	18 m16%	13 m14%	6 12%	1 4%	132 16%	14 12%	37 17%	46 18%	35 14%
Ranked 5th	210 21%	29 25%	12 20%	13 19%	16 18%	22 25%	12 17%	20 21%	14 16%	6 13%	29 25%	18 20%	13 26%	6 21%	173 21%	29 25%	41 19%	54 21%	49 20%
Not ranked	48 5%	5 Gm4%	6 CGm10%	1 1%	5 Gm6%	6 Gm7%	4 Gm6%	0 0%	4 Gm5%	3 7%	6 Gm5%	6 Gm7%	2 4%	0 0%	40 5%	5 4%	12 5%	10 4%	13 5%
Total	1003 100%	118 100%	60 100%	70 100%	90 100%	87 100%	71 100%	94 100%	85 100%	46 100%	114 100%	90 100%	50 100%	28 100%	835 100%	118 100%	220 100%	252 100%	245 100%

How the treatment is being used by my peers in a clinical setting

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
Ranked 1st	250 25%	24 20%	14 23%	28 ABGHJKL40%	23 26%	23 26%	21 30%	23 24%	19 22%	13 28%	28 25%	20 22%	8 16%	6 21%	216 26%	24 20%	65 30%	67 27%	60 24%
Ranked 2nd	246 25%	34 I29%	12 20%	20 I29%	22 24%	19 22%	22 I31%	19 20%	16 19%	6 13%	29 25%	25 I28%	11 22%	11 hi39%	199 24%	34 29%	54 25%	60 24%	51 21%
Ranked 3rd	189 19%	26 DF22%	9 15%	9 13%	10 11%	21 DF24%	6 8%	22 DF23%	20 DF24%	10 22%	24 DF21%	19 F21%	10 20%	3 11%	157 19%	26 P22%	28 13%	49 P19%	54 P22%
Ranked 4th	150 15%	17 C14%	11 C18%	4 6%	17 C19%	12 14%	13 C18%	16 C17%	13 C15%	7 15%	15 13%	11 12%	10 C20%	4 14%	125 15%	17 14%	32 15%	41 16%	35 14%
Ranked 5th	126 13%	13 11%	8 13%	8 11%	11 12%	8 9%	5 7%	14 15%	12 14%	7 15%	15 13%	11 12%	10 F20%	4 14%	101 12%	13 11%	27 12%	27 11%	34 14%
Not ranked	42 4%	4 Gm3%	6 CGm10%	1 1%	7 CGm8%	4 Gm5%	4 Gm6%	0 0%	5 Gm6%	3 7%	3 3%	4 Gm4%	1 2%	0 0%	37 4%	4 3%	14 6%	8 3%	11 4%
Total	1003 100%	118 100%	60 100%	70 100%	90 100%	87 100%	71 100%	94 100%	85 100%	46 100%	114 100%	90 100%	50 100%	28 100%	835 100%	118 100%	220 100%	252 100%	245 100%

What the adherence rates are in a clinical setting

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
Ranked 1st	57 6%	7 C6%	3 5%	0 0%	4 C4%	9 C10%	3 4%	7 C7%	4 C5%	5 C11%	6 C5%	3 3%	4 C8%	2 7%	48 6%	7 6%	7 3%	19 P8%	15 6%
Ranked 2nd	172 17%	12 10%	16 AF27%	14 20%	17 19%	17 20%	9 13%	14 15%	13 15%	10 22%	22 A19%	14 16%	11 22%	3 11%	144 17%	12 10%	47 O21%	40 16%	45 O18%
Ranked 3rd	244 24%	39 EJK33%	16 27%	15 21%	23 E26%	12 14%	24 EK34%	23 24%	18 21%	10 22%	24 21%	18 20%	16 E32%	6 21%	204 24%	39 R33%	54 25%	59 23%	52 21%
Ranked 4th	269 27%	37 BI31%	11 18%	21 30%	20 22%	23 26%	14 20%	23 24%	23 27%	7 15%	42 BDFIL37%	28 I31%	11 22%	9 32%	221 26%	37 31%	52 24%	60 24%	72 29%
Ranked 5th	211 21%	17 14%	9 15%	18 L26%	20 22%	22 JL25%	18 25%	27 ABJL29%	21 25%	11 24%	16 14%	20 22%	6 12%	6 21%	179 21%	17 14%	47 21%	67 O27%	48 20%
Not ranked	50 5%	6 G5%	5 G8%	2 3%	6 G7%	4 G5%	3 4%	0 0%	6 G7%	3 7%	4 G4%	7 G8%	2 4%	2 7%	39 5%	6 5%	13 6%	7 3%	13 5%
Total	1003 100%	118 100%	60 100%	70 100%	90 100%	87 100%	71 100%	94 100%	85 100%	46 100%	114 100%	90 100%	50 100%	28 100%	835 100%	118 100%	220 100%	252 100%	245 100%

How to best fit the treatment into the current protocol, including when to switch patients

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
Ranked 1st	298 30%	38 C32%	18 30%	13 19%	20 22%	26 30%	27 CD38%	29 31%	26 31%	11 24%	39 C34%	26 29%	14 28%	11 c39%	247 30%	38 32%	51 23%	82 P33%	76 31%
Ranked 2nd	232 23%	24 20%	12 20%	13 19%	21 23%	23 26%	16 23%	31 ACI33%	19 22%	8 17%	24 21%	23 26%	13 26%	5 18%	191 23%	24 20%	46 21%	70 28%	51 21%
Ranked 3rd	177 18%	18 15%	13 22%	15 I21%	22 I24%	12 14%	13 18%	14 15%	14 16%	4 9%	23 I20%	17 19%	9 18%	3 11%	148 18%	18 15%	50 Q23%	39 15%	41 17%
Ranked 4th	132 13%	21 HJ18%	5 8%	16 BFHJ23%	11 12%	11 13%	7 10%	11 12%	7 8%	11 BHJ24%	9 8%	10 11%	8 16%	5 18%	109 13%	21 18%	32 15%	29 12%	27 11%
Ranked 5th	128 13%	14 12%	7 12%	12 17%	11 12%	11 13%	5 7%	9 10%	14 16%	10 F22%	16 14%	10 11%	5 10%	4 14%	109 13%	14 12%	30 14%	25 10%	40 Q16%
Not ranked	36 4%	3 3%	5 Gm8%	1 1%	5 Gm6%	4 Gm5%	3 4%	0 0%	5 Gm6%	2 4%	3 3%	4 Gm4%	1 2%	0 0%	31 4%	3 3%	11 5%	7 3%	10 4%
Total	1003 100%	118 100%	60 100%	70 100%	90 100%	87 100%	71 100%	94 100%	85 100%	46 100%	114 100%	90 100%	50 100%	28 100%	835 100%	118 100%	220 100%	252 100%	245 100%

Real world evidence is not useful to me

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R
Real world evidence is not useful to me	30 3%	3 3%	4 GLm7%	1 1%	4 GLm4%	3 3%	3 4%	0 0%	4 GLm5%	2 4%	2 2%	4 GLm4%	0 0%	0 0%	26 3%	3 3%	9 4%	6 2%	8 3%
Total	1003 100%	118 100%	60 100%	70 100%	90 100%	87 100%	71 100%	94 100%	85 100%	46 100%	114 100%	90 100%	50 100%	28 100%	835 100%	118 100%	220 100%	252 100%	245 100%

Absolutes/col percents

Table 9
Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice.

Base: All respondents

Column key — S2 - GP type: A = GP Principal, B = Salaried GP, C = GP Registrar, D = Locum GP. D3 - Gender: E = Male, F = Female. D4 - Year of qualification: G = 1979 or earlier, H = 1980-1989, I = 1990-1999, J = 2000-2010. D6 - Age: K = Under 30, L = 30-39, M = 40-49, N = 50-59, O = 60 or over. D8 - CCG Involvement: I am, or plan to be, an active member of my CCG governing board / I am, or plan to be, a GP representative / I do not take an active part in my CCG.

What the patient preference is for the treatment

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	CCG board	CCG rep	CCG none
Ranked 1st	93 9%	60 c9%	21 c9%	0 0%	12 c10%	62 F11%	31 7%	13 16%	18 8%	24 8%	38 10%	1 11%	38 11%	23 7%	21 8%	10 13%	12 13%	13 8%	50 8%
Ranked 2nd	148 15%	82 12%	41 A18%	1 50%	24 A20%	84 15%	64 15%	13 16%	28 12%	39 13%	68 H18%	2 22%	66 MN19%	40 13%	29 12%	11 15%	13 14%	20 13%	93 16%
Ranked 3rd	220 22%	146 22%	51 23%	1 50%	22 18%	114 20%	106 24%	16 19%	52 22%	71 23%	81 22%	3 33%	76 21%	76 24%	52 21%	13 17%	19 21%	37 24%	128 22%
Ranked 4th	239 24%	163 c25%	49 c22%	0 0%	27 c23%	140 25%	99 23%	23 28%	70 J29%	68 22%	78 21%	1 11%	70 20%	71 22%	77 LM31%	20 27%	22 24%	39 25%	139 23%
Ranked 5th	262 26%	179 c27%	52 c23%	0 0%	31 c26%	144 25%	118 27%	17 20%	64 27%	90 29%	91 24%	2 22%	83 23%	96 L30%	60 24%	21 28%	21 23%	34 22%	164 28%
Not ranked	41 4%	27 c4%	11 c5%	0 0%	3 3%	22 4%	19 4%	1 1%	7 3%	14 G5%	19 G5%	0 0%	21 kO6%	11 kO3%	9 kO4%	0 0%	3 3%	10 7%	21 4%
Total	1003 100%	657 100%	225 100%	2 100%	119 100%	566 100%	437 100%	83 100%	239 100%	306 100%	375 100%	9 100%	354 100%	317 100%	248 100%	75 100%	90 100%	153 100%	595 100%

That use in clinical settings validates the phase 3 trial data

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	CCG board	CCG rep	CCG none
Ranked 1st	275 27%	180 27%	60 27%	1 50%	34 29%	150 27%	125 29%	21 25%	78 J33%	86 28%	90 24%	3 33%	79 22%	92 L29%	79 L32%	22 29%	25 28%	38 25%	161 27%
Ranked 2nd	175 17%	123 c19%	35 c16%	0 0%	17 c14%	102 18%	73 17%	14 17%	45 19%	56 18%	60 16%	2 22%	57 16%	56 18%	45 18%	15 20%	15 17%	28 18%	108 18%
Ranked 3rd	143 14%	98 c15%	26 c12%	0 0%	19 c16%	92 F16%	51 12%	14 17%	38 16%	34 11%	57 15%	0 0%	55 k16%	38 k12%	38 k15%	12 k16%	16 18%	24 16%	77 13%
Ranked 4th	152 15%	96 c15%	32 c14%	0 0%	24 c20%	76 13%	76 17%	13 16%	31 13%	51 17%	57 15%	0 0%	58 k16%	55 k17%	29 k12%	10 k13%	15 17%	21 14%	97 16%
Ranked 5th	210 21%	130 20%	58 26%	1 50%	21 18%	123 22%	87 20%	19 23%	42 18%	60 20%	89 24%	4 44%	82 23%	59 19%	50 20%	15 20%	16 18%	29 19%	128 22%
Not ranked	48 5%	30 c5%	14 c6%	0 0%	4 c3%	23 4%	25 6%	2 2%	5 2%	19 H6%	22 H6%	0 0%	23 kNO6%	17 kO5%	7 k3%	1 1%	3 3%	13 8%	24 4%
Total	1003 100%	657 100%	225 100%	2 100%	119 100%	566 100%	437 100%	83 100%	239 100%	306 100%	375 100%	9 100%	354 100%	317 100%	248 100%	75 100%	90 100%	153 100%	595 100%

How the treatment is being used by my peers in a clinical setting

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	CCG board	CCG rep	CCG none
Ranked 1st	250 25%	171 26%	51 23%	1 50%	27 23%	142 25%	108 25%	17 20%	59 25%	82 27%	92 25%	1 11%	85 24%	89 28%	58 23%	17 23%	24 27%	31 20%	161 27%
Ranked 2nd	246 25%	155 c24%	66 c29%	0 0%	25 c21%	125 22%	121 E28%	19 23%	69 J29%	78 25%	80 21%	1 11%	75 21%	84 26%	69 28%	17 23%	19 21%	36 24%	145 24%
Ranked 3rd	189 19%	123 c19%	39 c17%	0 0%	27 c23%	110 19%	79 18%	16 19%	37 15%	55 18%	81 22%	3 33%	78 N22%	55 17%	38 15%	15 20%	17 19%	30 20%	111 19%
Ranked 4th	150 15%	95 c14%	34 c15%	0 0%	21 c18%	92 16%	58 13%	16 19%	30 13%	42 14%	62 17%	4 44%	51 14%	44 14%	37 15%	14 19%	10 11%	24 16%	91 15%
Ranked 5th	126 13%	88 13%	22 10%	1 50%	15 13%	76 13%	50 11%	13 16%	39 J16%	35 11%	39 10%	0 0%	43 k12%	33 k10%	39 k16%	11 k15%	17 19%	20 13%	65 11%
Not ranked	42 4%	25 c4%	13 c6%	0 0%	4 c3%	21 4%	21 5%	2 2%	5 2%	14 5%	21 H6%	0 0%	22 kNO6%	12 k4%	7 k3%	1 1%	3 3%	12 8%	22 4%
Total	1003 100%	657 100%	225 100%	2 100%	119 100%	566 100%	437 100%	83 100%	239 100%	306 100%	375 100%	9 100%	354 100%	317 100%	248 100%	75 100%	90 100%	153 100%	595 100%

What the adherence rates are in a clinical setting

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	CCG board	CCG rep	CCG none
Ranked 1st	57 6%	42 c6%	10 c4%	0 0%	5 c4%	35 6%	22 5%	8 10%	9 4%	18 6%	22 6%	1 11%	23 6%	16 5%	11 4%	6 8%	7 8%	13 8%	29 5%
Ranked 2nd	172 17%	114 17%	38 17%	1 50%	19 16%	104 18%	68 16%	26 HIJ31%	33 14%	55 18%	58 15%	2 22%	54 15%	56 18%	40 16%	20 L27%	19 21%	25 16%	100 17%
Ranked 3rd	244 24%	157 c24%	59 c26%	0 0%	28 c24%	137 24%	107 24%	14 17%	66 G28%	76 25%	88 23%	1 11%	79 22%	81 26%	69 28%	14 19%	19 21%	35 23%	150 25%
Ranked 4th	269 27%	174 26%	60 27%	1 50%	34 29%	154 27%	115 26%	17 20%	68 28%	76 25%	108 29%	4 44%	106 30%	79 25%	61 25%	19 25%	21 23%	31 20%	169 28%
Ranked 5th	211 21%	137 c21%	46 c20%	0 0%	28 c24%	116 20%	95 22%	17 20%	55 23%	63 21%	76 20%	1 11%	67 19%	70 22%	57 23%	16 21%	20 22%	37 24%	124 21%
Not ranked	50 5%	33 c5%	12 c5%	0 0%	5 c4%	20 4%	30 E7%	1 1%	8 3%	18 G6%	23 G6%	0 0%	25 kO7%	15 kO5%	10 kO4%	0 0%	4 4%	12 8%	23 4%
Total	1003 100%	657 100%	225 100%	2 100%	119 100%	566 100%	437 100%	83 100%	239 100%	306 100%	375 100%	9 100%	354 100%	317 100%	248 100%	75 100%	90 100%	153 100%	595 100%

How to best fit the treatment into the current protocol, including when to switch patients

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	CCG board	CCG rep	CCG none
Ranked 1st	298 30%	185 c28%	75 c33%	0 0%	38 c32%	162 29%	136 31%	23 28%	71 30%	86 28%	118 31%	3 33%	113 32%	89 28%	73 29%	20 27%	20 22%	51 33%	177 30%
Ranked 2nd	232 23%	164 Bc25%	37 c16%	0 0%	31 Bc26%	136 24%	96 22%	10 12%	60 G25%	68 G22%	94 G25%	2 22%	86 24%	73 23%	59 24%	12 16%	22 24%	37 24%	132 22%
Ranked 3rd	177 18%	114 17%	42 19%	1 50%	20 17%	98 17%	79 18%	22 J27%	42 18%	60 20%	53 14%	2 22%	50 14%	59 19%	45 18%	21 L28%	17 19%	20 13%	112 19%
Ranked 4th	132 13%	90 D14%	33 D15%	1 50%	8 7%	74 13%	58 13%	12 14%	32 13%	47 15%	41 11%	0 0%	38 k11%	49 k15%	34 k14%	11 k15%	18 20%	21 14%	71 12%
Ranked 5th	128 13%	81 c12%	29 c13%	0 0%	18 c15%	77 14%	51 12%	15 18%	29 12%	34 11%	50 13%	2 22%	47 13%	38 12%	30 12%	11 15%	11 12%	16 10%	82 14%
Not ranked	36 4%	23 c4%	9 c4%	0 0%	4 c3%	19 3%	17 4%	1 1%	5 2%	11 4%	19 GH5%	0 0%	20 kO6%	9 kO3%	7 kO3%	0 0%	2 2%	8 5%	21 4%
Total	1003 100%	657 100%	225 100%	2 100%	119 100%	566 100%	437 100%	83 100%	239 100%	306 100%	375 100%	9 100%	354 100%	317 100%	248 100%	75 100%	90 100%	153 100%	595 100%

Real world evidence is not useful to me

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	CCG board	CCG rep	CCG none
Real world evidence is not useful to me	30 3%	19 c3%	8 c4%	0 0%	3 3%	15 3%	15 3%	1 1%	4 2%	10 3%	15 4%	0 0%	16 kO5%	8 kO3%	6 kO2%	0 0%	2 2%	7 5%	17 3%
Total	1003 100%	657 100%	225 100%	2 100%	119 100%	566 100%	437 100%	83 100%	239 100%	306 100%	375 100%	9 100%	354 100%	317 100%	248 100%	75 100%	90 100%	153 100%	595 100%

COMRES

Absolutes/col percents

Table 10
Q1 Thinking about where real world evidence could add value in such a scenario, please rank the following information in order of how useful it would be in informing your prescribing practice?

Base: All respondents

Column key — D2 Practice Location: A Rural area, B Urban area, C Semi-rural area, D Suburban area, E Other; D1 Overall practice size: F 1-2, G 3-5, H 6-10, I 11 or more; D5 Dispensing Practice: J Yes, K No; D7 Number of patients on practice list: L 1-2500, M 2501-5000, N 5001-7500, O 7501-10000, P 10001+

What the patient preference is for the treatment

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
Ranked 1st	93 9%	10 11%	38 9%	22 9%	22 8%	1 20%	11 17%	36 9%	38 9%	8 9%	18 10%	75 9%	7 18%	9 6%	20 9%	22 10%	35 10%
Ranked 2nd	148 15%	13 14%	58 14%	30 13%	46 17%	1 20%	8 13%	62 15%	66 15%	12 13%	25 13%	123 15%	3 8%	23 15%	31 14%	40 17%	51 15%
Ranked 3rd	220 22%	19 20%	85 21%	67 BD29%	48 18%	1 20%	18 29%	92 22%	94 22%	16 18%	47 25%	173 21%	8 21%	38 24%	53 24%	45 19%	76 22%
Ranked 4th	239 24%	23 24%	100 25%	55 23%	59 22%	2 40%	9 14%	98 24%	108 F25%	24 27%	43 23%	196 24%	7 18%	39 25%	48 21%	55 24%	90 26%
Ranked 5th	262 26%	27 e29%	105 e26%	55 e23%	75 e28%	0 0%	13 21%	108 26%	115 26%	26 29%	49 26%	213 26%	12 31%	41 26%	64 28%	60 26%	85 24%
Not ranked	41 4%	2 2%	17 e4%	6 e3%	16 e6%	0 0%	4 6%	17 4%	16 4%	4 4%	7 4%	34 4%	2 5%	8 5%	9 4%	9 4%	13 4%
Total	1003 100%	94 100%	403 100%	235 100%	266 100%	5 100%	63 100%	413 100%	437 100%	90 100%	189 100%	814 100%	39 100%	158 100%	225 100%	231 100%	350 100%

That use in clinical settings validates the phase 3 trial data

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
Ranked 1st	275 27%	23 24%	112 28%	65 28%	74 28%	1 20%	13 21%	128 I31%	116 27%	18 20%	43 23%	232 29%	6 15%	48 L30%	70 L31%	66 L29%	85 24%
Ranked 2nd	175 17%	19 20%	72 18%	41 17%	41 15%	2 40%	10 16%	64 15%	88 20%	13 14%	34 18%	141 17%	9 23%	21 13%	44 20%	39 17%	62 18%
Ranked 3rd	143 14%	16 e17%	53 e13%	32 e14%	42 e16%	0 0%	12 19%	53 13%	57 13%	21 GH23%	30 16%	113 14%	7 18%	28 N18%	17 8%	34 N15%	57 N16%
Ranked 4th	152 15%	14 15%	56 14%	44 19%	37 14%	1 20%	12 19%	70 17%	58 13%	12 13%	37 20%	115 14%	6 15%	32 20%	35 16%	33 14%	46 13%
Ranked 5th	210 21%	20 21%	88 22%	46 20%	55 21%	1 20%	12 19%	75 18%	101 23%	22 24%	39 21%	171 21%	9 23%	22 14%	46 20%	45 19%	88 M25%
Not ranked	48 5%	2 2%	22 e5%	7 e3%	17 Ae6%	0 0%	4 6%	23 6%	17 4%	4 4%	6 3%	42 5%	2 5%	7 4%	13 6%	14 6%	12 3%
Total	1003 100%	94 100%	403 100%	235 100%	266 100%	5 100%	63 100%	413 100%	437 100%	90 100%	189 100%	814 100%	39 100%	158 100%	225 100%	231 100%	350 100%

How the treatment is being used by my peers in a clinical setting

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
Ranked 1st	250 25%	25 27%	88 22%	68 B29%	68 26%	1 20%	16 25%	95 23%	113 26%	26 29%	61 K32%	189 23%	11 28%	39 25%	54 24%	62 27%	84 24%
Ranked 2nd	246 25%	22 23%	108 27%	55 23%	60 23%	1 20%	18 29%	103 25%	103 24%	22 24%	40 21%	206 25%	12 31%	48 N30%	44 20%	54 23%	88 25%
Ranked 3rd	189 19%	19 20%	79 20%	37 16%	53 20%	1 20%	3 5%	78 F19%	89 F20%	19 F21%	35 19%	154 19%	4 10%	24 15%	47 21%	39 17%	75 L21%
Ranked 4th	150 15%	13 e14%	58 e14%	39 e17%	40 e15%	0 0%	11 I17%	69 I17%	64 I15%	6 7%	21 11%	129 16%	5 13%	23 15%	35 16%	42 18%	45 13%
Ranked 5th	126 13%	12 13%	52 13%	31 13%	29 11%	2 40%	10 16%	48 12%	54 12%	14 16%	25 13%	101 12%	4 10%	16 10%	35 16%	23 10%	48 14%
Not ranked	42 4%	3 3%	18 e4%	5 e2%	16 Ce6%	0 0%	5 8%	20 5%	14 3%	3 3%	7 4%	35 4%	3 8%	8 5%	10 4%	11 5%	10 3%
Total	1003 100%	94 100%	403 100%	235 100%	266 100%	5 100%	63 100%	413 100%	437 100%	90 100%	189 100%	814 100%	39 100%	158 100%	225 100%	231 100%	350 100%

What the adherence rates are in a clinical setting

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
Ranked 1st	57 6%	6 e6%	22 e5%	11 e5%	18 e7%	0 0%	3 5%	27 7%	20 5%	7 8%	12 6%	45 6%	2 5%	8 5%	14 6%	7 3%	26 O7%
Ranked 2nd	172 17%	17 18%	72 18%	38 16%	44 17%	1 20%	10 16%	78 19%	68 16%	16 18%	34 18%	138 17%	8 21%	23 15%	45 20%	40 17%	56 16%
Ranked 3rd	244 24%	16 17%	104 A26%	55 23%	68 26%	1 20%	14 22%	106 26%	105 24%	19 21%	36 19%	208 J26%	9 23%	32 20%	60 27%	60 26%	83 24%
Ranked 4th	269 27%	30 32%	109 27%	56 24%	72 27%	2 40%	18 29%	91 22%	132 G30%	28 31%	53 28%	216 27%	12 31%	45 28%	54 24%	55 24%	103 29%
Ranked 5th	211 21%	22 23%	76 19%	66 BD28%	46 17%	1 20%	14 22%	90 22%	90 21%	17 19%	46 24%	165 20%	6 15%	43 N27%	39 17%	54 23%	69 20%
Not ranked	50 5%	3 3%	20 e5%	9 e4%	18 e7%	0 0%	4 6%	21 5%	22 5%	3 3%	8 4%	42 5%	2 5%	7 4%	13 6%	15 6%	13 4%
Total	1003 100%	94 100%	403 100%	235 100%	266 100%	5 100%	63 100%	413 100%	437 100%	90 100%	189 100%	814 100%	39 100%	158 100%	225 100%	231 100%	350 100%

How to best fit the treatment into the current protocol, including when to switch patients

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
Ranked 1st	298 30%	28 30%	132 33%	64 27%	72 27%	2 40%	16 25%	115 28%	139 32%	28 31%	51 27%	247 30%	11 28%	47 30%	60 27%	68 29%	112 32%
Ranked 2nd	232 23%	21 e22%	82 e20%	66 Be28%	63 e24%	0 0%	13 21%	94 23%	101 23%	24 27%	52 28%	180 22%	5 13%	36 23%	54 24%	52 23%	85 L24%
Ranked 3rd	177 18%	22 23%	71 18%	39 17%	43 16%	2 40%	12 19%	72 17%	81 19%	12 13%	37 20%	140 17%	9 23%	29 18%	41 18%	47 20%	51 15%
Ranked 4th	132 13%	11 e12%	52 e13%	33 e14%	36 e14%	0 0%	8 13%	56 14%	52 12%	16 18%	25 13%	107 13%	6 15%	11 7%	38 M17%	26 11%	51 M15%
Ranked 5th	128 13%	9 10%	53 13%	27 11%	38 14%	1 20%	9 14%	62 I15%	51 12%	6 7%	17 9%	111 14%	5 13%	28 18%	25 11%	29 13%	41 12%
Not ranked	36 4%	3 3%	13 e3%	6 e3%	14 e5%	0 0%	5 8%	14 3%	13 3%	4 4%	7 4%	29 4%	3 8%	7 4%	7 3%	9 4%	10 3%
Total	1003 100%	94 100%	403 100%	235 100%	266 100%	5 100%	63 100%	413 100%	437 100%	90 100%	189 100%	814 100%	39 100%	158 100%	225 100%	231 100%	350 100%

	Total	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
Real world evidence is not useful to me	30 3%	2 2%	11 e3%	5 e2%	12 e5%	0 0%	4 6%	12 3%	11 3%	3 3%	4 2%	26 3%	2 5%	7 4%	7 3%	6 3%	8 2%
Total	1003 100%	94 100%	403 100%	235 100%	266 100%	5 100%	63 100%	413 100%	437 100%	90 100%	189 100%	814 100%	39 100%	158 100%	225 100%	231 100%	350 100%

Absolutes/col percents

Table 11
Q2 If such evidence were peer reviewed would it then be of use to you?

Base: All respondents

	Total		S3 - Region																S3 - England		S3 - England NHS Networks			
			London		South East Coastal		South Central		South West		West Midlands		East Midlands		East of England		Yorkshire & Humber		North East		North West		Scotland		Wales		Northern Ireland		England		NHS London		NHS South of England		NHS Midlands and East SHA		NHS North of England
			A		B		C		D		E		F		G		H		I		J		K		L		M		N		O		P		Q		R
Yes, peer reviewed evidence would be of use to me	26	87%	2	67%	4	100%	1	100%	2	50%	3	100%	2	67%	0	0%	4	100%	2	100%	2	100%	4	100%	0	0%	0	0%	22	85%	2	67%	7	78%	5	83%	8	100%
No, peer reviewed evidence would still be of no use to me	4	13%	1	33%	0	0%	0	0%	2	50%	0	0%	1	33%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	0	0%	4	15%	1	33%	2	22%	1	17%	0	0%
Total	30	100%	3	100%	4	100%	1	100%	4	100%	3	100%	3	100%	0	100%	4	100%	2	100%	2	100%	4	100%	0	100%	0	100%	26	100%	3	100%	9	100%	6	100%	8	100%

Prepared by ComRes

ComRes

Absolutes/col percents

Table 12
Q2 If such evidence were peer reviewed would it then be of use to you?

Base: All respondents

	Total		S2 - GP type					D3 - Gender			D4 - Year of qualification					D6 - Age						D8 - CCG Involvement		
			GP Principal	Salaried GP	GP Registrar	Locum GP		Male	Female		1979 or earlier	1980-1989	1990-1999	2000-2010		Under 30	30 – 39	40 – 49	50 – 59	60 or over		I am, or plan to be, an active member of my CCG governing board	I am, or plan to be, a GP representative	I do not take an active part in my CCG
			A	B	C	D		E	F		G	H	I	J		K	L	M	N	O				
Yes, peer reviewed evidence would be of use to me	26	87%	16	84%	7	88%	0	0%	3	100%	11	73%	15	e100%	1	100%	4	100%	8	80%	13	87%	0	0%	13	81%	7	88%	6	100%	0	0%	0	0%	6	86%	16	94%
No, peer reviewed evidence would still be of no use to me	4	13%	3	16%	1	13%	0	0%	0	0%	4	f27%	0	0%	0	0%	0	0%	2	20%	2	13%	0	0%	3	19%	1	13%	0	0%	0	0%	2	100%	1	14%	1	6%
Total	30	100%	19	100%	8	100%	0	100%	3	100%	15	100%	15	100%	1	100%	4	100%	10	100%	15	100%	0	100%	16	100%	8	100%	6	100%	0	100%	2	100%	7	100%	17	100%

Prepared by ComRes

Absolutes/col percents

Table 13
Q2 If such evidence were peer reviewed would it then be of use to you?

Base: All respondents

	Total		D2 - Practice Location									D1 - Overall practice size								D5 - Dispensing Practice				D7 - Number of patients on practice list									
			Rural area		Urban area		Semi-rural area		Suburban area		Other		1-2		3-5		6-10		11 or more		Yes		No		1-2500		2501-5000		5001-7500		7501-10000		10001+	
			A		B		C		D		E		F		G		H		I		J		K		L		M		N		O		P	
Yes, peer reviewed evidence would be of use to me	26	87%	1	50%	10	91%	3	60%	12	100%	0	0%	4	100%	11	92%	9	82%	2	67%	3	75%	23	88%	2	100%	7	100%	6	86%	5	83%	6	75%
No, peer reviewed evidence would still be of no use to me	4	13%	1	50%	1	9%	2	40%	0	0%	0	0%	0	0%	1	8%	2	18%	1	33%	1	25%	3	12%	0	0%	0	0%	1	14%	1	17%	2	25%
Total	30	100%	2	100%	11	100%	5	100%	12	100%	0	100%	4	100%	12	100%	11	100%	3	100%	4	100%	26	100%	2	100%	7	100%	7	100%	6	100%	8	100%

Prepared by ComRes

Importance of evidence in your adoption of new treatments

ONLINE Fieldwork Dates: 12th-21st August 2015

Table 14

Absolutes/col percents

Q3 Assuming that the real world evidence such as registry data or clinical audit has been peer reviewed, please rank the following information in order of how useful it would be in informing your prescribing practice?

Base: All qualifying respondents
Summary table

	Ranking						Top 3	Mean
	Ranked 1st	Ranked 2nd	Ranked 3rd	Ranked 4th	Ranked 5th	Not ranked	Ranked in Top 3	Mean ranking
Base	26	26	26	26	26	26	26	26
How the treatment is being used by my peers in a clinical setting	13	7	3	1	2	0	23	26
	50%	27%	12%	4%	8%	0%	88%	4.08
How to best fit the treatment into the current protocol, including when to switch patients	6	4	7	5	4	0	17	26
	23%	15%	27%	19%	15%	0%	65%	3.12
That use in clinical settings validates the phase 3 trial data	6	5	2	6	7	0	13	26
	23%	19%	8%	23%	27%	0%	50%	2.88
What the adherence rates are in a clinical setting	1	4	10	9	1	1	15	26
	4%	15%	38%	35%	4%	4%	58%	2.69
What the patient preference is for the treatment	0	6	4	4	11	1	10	26
	0%	23%	15%	15%	42%	4%	38%	2.12

Prepared by ComRes

COMRES

Absolutes/col percents

Table 15
Q3 Assuming that the real world evidence such as registry data or clinical audit has been peer reviewed, please rank the following information in order of how useful it would be in informing your prescribing practice?

Base: All respondents

What the patient preference is for the treatment

	Total	London (A)	South East Coastal (B)	South Central (C)	South West (D)	West Midlands (E)	East Midlands (F)	East of England (G)	Yorkshire & Humber (H)	North East (I)	North West (J)	Scotland (K)	Wales (L)	Northern Ireland (M)	England (N)	NHS London (O)	NHS South of England (P)	NHS Midlands and East SHA (Q)	NHS North of England (R)
Ranked 1st	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ranked 2nd	6 23%	1 50%	1 25%	0 0%	1 50%	1 33%	0 0%	0 0%	0 0%	1 50%	1 50%	0 0%	0 0%	0 0%	6 27%	1 50%	2 29%	1 20%	2 25%
Ranked 3rd	4 15%	1 50%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	1 25%	0 0%	0 0%	1 25%	0 0%	0 0%	3 14%	1 50%	0 0%	1 20%	1 13%
Ranked 4th	4 15%	0 0%	1 25%	1 **bh**100%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	1 50%	0 0%	0 0%	0 0%	4 18%	0 0%	2 29%	0 0%	2 25%
Ranked 5th	11 42%	0 0%	2 50%	0 0%	1 50%	2 67%	1 50%	0 0%	2 50%	0 0%	0 0%	3 **acij**75%	0 0%	0 0%	8 36%	0 0%	3 43%	3 **o**60%	2 25%
Not ranked	1 4%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	1 5%	0 0%	0 0%	0 0%	1 13%
Total	26 100%	2 100%	4 100%	1 100%	2 100%	3 100%	2 100%	0 100%	4 100%	2 100%	2 100%	4 100%	0 100%	0 100%	22 100%	2 100%	7 100%	5 100%	8 100%

That use in clinical settings validates the phase 3 trial data

	Total	London (A)	South East Coastal (B)	South Central (C)	South West (D)	West Midlands (E)	East Midlands (F)	East of England (G)	Yorkshire & Humber (H)	North East (I)	North West (J)	Scotland (K)	Wales (L)	Northern Ireland (M)	England (N)	NHS London (O)	NHS South of England (P)	NHS Midlands and East SHA (Q)	NHS North of England (R)
Ranked 1st	6 23%	0 0%	2 50%	0 0%	0 0%	2 67%	0 0%	0 0%	1 25%	0 0%	0 0%	1 25%	0 0%	0 0%	5 23%	0 0%	2 29%	2 40%	1 13%
Ranked 2nd	5 19%	0 0%	0 0%	0 0%	1 50%	0 0%	1 50%	0 0%	1 25%	0 0%	0 0%	2 50%	0 0%	0 0%	3 14%	0 0%	1 14%	1 20%	1 13%
Ranked 3rd	2 8%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	2 9%	1 50%	0 0%	0 0%	1 13%
Ranked 4th	6 23%	1 50%	0 0%	0 0%	1 50%	0 0%	1 50%	0 0%	1 25%	0 0%	1 50%	1 25%	0 0%	0 0%	5 23%	1 50%	1 14%	1 20%	2 25%
Ranked 5th	7 27%	0 0%	2 50%	1 **h**100%	0 0%	1 33%	0 0%	0 0%	1 25%	1 50%	1 50%	0 0%	0 0%	0 0%	7 32%	0 0%	3 43%	1 20%	3 38%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	2 100%	4 100%	1 100%	2 100%	3 100%	2 100%	0 100%	4 100%	2 100%	2 100%	4 100%	0 100%	0 100%	22 100%	2 100%	7 100%	5 100%	8 100%

How the treatment is being used by my peers in a clinical setting

	Total	London (A)	South East Coastal (B)	South Central (C)	South West (D)	West Midlands (E)	East Midlands (F)	East of England (G)	Yorkshire & Humber (H)	North East (I)	North West (J)	Scotland (K)	Wales (L)	Northern Ireland (M)	England (N)	NHS London (O)	NHS South of England (P)	NHS Midlands and East SHA (Q)	NHS North of England (R)
Ranked 1st	13 50%	1 50%	1 25%	0 0%	2 **b**100%	1 33%	1 50%	0 0%	3 **c**75%	1 50%	1 50%	2 50%	0 0%	0 0%	11 50%	1 50%	3 43%	2 40%	5 63%
Ranked 2nd	7 27%	0 0%	2 50%	1 **hk**100%	0 0%	1 33%	1 50%	0 0%	1 25%	0 0%	0 0%	1 25%	0 0%	0 0%	6 27%	0 0%	3 43%	2 40%	1 13%
Ranked 3rd	3 12%	0 0%	1 25%	0 0%	0 0%	1 33%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	3 14%	0 0%	1 14%	1 20%	1 13%
Ranked 4th	1 4%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ranked 5th	2 8%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	2 9%	1 50%	0 0%	0 0%	1 13%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	2 100%	4 100%	1 100%	2 100%	3 100%	2 100%	0 100%	4 100%	2 100%	2 100%	4 100%	0 100%	0 100%	22 100%	2 100%	7 100%	5 100%	8 100%

What the adherence rates are in a clinical setting

	Total	London (A)	South East Coastal (B)	South Central (C)	South West (D)	West Midlands (E)	East Midlands (F)	East of England (G)	Yorkshire & Humber (H)	North East (I)	North West (J)	Scotland (K)	Wales (L)	Northern Ireland (M)	England (N)	NHS London (O)	NHS South of England (P)	NHS Midlands and East SHA (Q)	NHS North of England (R)
Ranked 1st	1 4%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ranked 2nd	4 15%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 25%	0 0%	1 50%	1 25%	0 0%	0 0%	3 14%	1 50%	0 0%	0 0%	2 25%
Ranked 3rd	10 38%	0 0%	3 **afik**75%	1 100%	2 100%	1 33%	0 0%	0 0%	2 50%	0 0%	1 50%	0 0%	0 0%	0 0%	10 45%	0 0%	6 **oqr**86%	1 20%	3 38%
Ranked 4th	9 35%	1 50%	1 25%	0 0%	0 0%	2 67%	1 50%	0 0%	1 25%	1 50%	0 0%	2 50%	0 0%	0 0%	7 32%	1 50%	1 14%	3 60%	2 25%
Ranked 5th	1 4%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 5%	0 0%	0 0%	1 20%	0 0%
Not ranked	1 4%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	0 0%	1 5%	0 0%	0 0%	0 0%	1 13%
Total	26 100%	2 100%	4 100%	1 100%	2 100%	3 100%	2 100%	0 100%	4 100%	2 100%	2 100%	4 100%	0 100%	0 100%	22 100%	2 100%	7 100%	5 100%	8 100%

How to best fit the treatment into the current protocol, including when to switch patients

	Total	London (A)	South East Coastal (B)	South Central (C)	South West (D)	West Midlands (E)	East Midlands (F)	East of England (G)	Yorkshire & Humber (H)	North East (I)	North West (J)	Scotland (K)	Wales (L)	Northern Ireland (M)	England (N)	NHS London (O)	NHS South of England (P)	NHS Midlands and East SHA (Q)	NHS North of England (R)
Ranked 1st	6 23%	1 50%	1 25%	1 **b**100%	0 0%	0 0%	1 50%	0 0%	0 0%	1 50%	1 50%	0 0%	0 0%	0 0%	6 27%	1 50%	2 29%	1 20%	2 25%
Ranked 2nd	4 15%	0 0%	1 25%	0 0%	0 0%	1 33%	0 0%	0 0%	1 25%	1 50%	0 0%	0 0%	0 0%	0 0%	4 18%	0 0%	1 14%	1 20%	2 25%
Ranked 3rd	7 27%	0 0%	0 0%	0 0%	0 0%	1 33%	1 50%	0 0%	1 25%	0 0%	1 50%	3 **abcdi**75%	0 0%	0 0%	4 18%	0 0%	0 0%	2 40%	2 25%
Ranked 4th	5 19%	0 0%	2 50%	0 0%	1 50%	1 33%	0 0%	0 0%	1 25%	0 0%	0 0%	0 0%	0 0%	0 0%	5 23%	0 0%	3 43%	1 20%	1 13%
Ranked 5th	4 15%	1 50%	0 0%	0 0%	1 50%	0 0%	0 0%	0 0%	1 25%	0 0%	0 0%	1 25%	0 0%	0 0%	3 14%	1 50%	1 14%	0 0%	1 13%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	2 100%	4 100%	1 100%	2 100%	3 100%	2 100%	0 100%	4 100%	2 100%	2 100%	4 100%	0 100%	0 100%	22 100%	2 100%	7 100%	5 100%	8 100%

Absolutes/col percents

Table 16
Q3 Assuming that the real world evidence such as registry data or clinical audit has been peer reviewed, please rank the following information in order of how useful it would be in informing your prescribing practice?

Base: All respondents

What the patient preference is for the treatment

	Total	A GP Principal	B Salaried GP	C GP Registrar	D Locum GP	E Male	F Female	G 1979 or earlier	H 1980-1989	I 1990-1999	J 2000-2010	K Under 30	L 30-39	M 40-49	N 50-59	O 60 or over	CCG gov board	CCG GP rep	CCG no active part
Ranked 1st	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ranked 2nd	6 23%	4 d25%	2 29%	0 0%	0 0%	4 36%	2 13%	0 0%	0 0%	4 gh50%	2 15%	0 0%	2 15%	3 43%	1 17%	0 0%	0 0%	1 17%	5 31%
Ranked 3rd	4 15%	2 13%	2 29%	0 0%	0 0%	1 9%	3 20%	0 0%	0 0%	0 0%	4 ghi31%	0 0%	4 mn31%	0 0%	0 0%	0 0%	0 0%	0 0%	3 19%
Ranked 4th	4 15%	4 bd25%	0 0%	0 0%	0 0%	1 9%	3 20%	1 ij100%	0 0%	1 13%	2 15%	0 0%	2 15%	1 14%	1 17%	0 0%	0 0%	1 17%	3 19%
Ranked 5th	11 42%	5 31%	3 43%	0 0%	3 ab100%	5 45%	6 40%	0 0%	4 ij100%	2 25%	5 g38%	0 0%	5 38%	2 29%	4 67%	0 0%	0 0%	3 50%	5 31%
Not ranked	1 4%	1 6%	0 0%	0 0%	0 0%	0 0%	1 7%	0 0%	0 0%	1 13%	0 0%	0 0%	0 0%	1 14%	0 0%	0 0%	0 0%	1 17%	0 0%
Total	26 100%	16 100%	7 100%	0 100%	3 100%	11 100%	15 100%	1 100%	4 100%	8 100%	13 100%	0 100%	13 100%	7 100%	6 100%	0 100%	0 100%	6 100%	16 100%

That use in clinical settings validates the phase 3 trial data

	Total	A GP Principal	B Salaried GP	C GP Registrar	D Locum GP	E Male	F Female	G 1979 or earlier	H 1980-1989	I 1990-1999	J 2000-2010	K Under 30	L 30-39	M 40-49	N 50-59	O 60 or over	CCG gov board	CCG GP rep	CCG no active part
Ranked 1st	6 23%	4 b25%	0 0%	0 0%	2 b67%	3 27%	3 20%	0 0%	2 50%	1 13%	3 23%	0 0%	3 23%	1 14%	2 33%	0 0%	0 0%	3 50%	2 13%
Ranked 2nd	5 19%	3 19%	2 29%	0 0%	0 0%	0 0%	5 e33%	0 0%	1 25%	0 0%	4 gi31%	0 0%	4 m31%	0 0%	1 17%	0 0%	0 0%	0 0%	3 19%
Ranked 3rd	2 8%	2 13%	0 0%	0 0%	0 0%	1 9%	1 7%	0 0%	0 0%	1 13%	1 8%	0 0%	1 8%	1 14%	0 0%	0 0%	0 0%	1 17%	1 6%
Ranked 4th	6 23%	3 19%	2 29%	0 0%	1 33%	4 36%	2 13%	0 0%	1 25%	2 25%	3 23%	0 0%	3 23%	1 14%	2 33%	0 0%	0 0%	1 17%	4 25%
Ranked 5th	7 27%	4 d25%	3 43%	0 0%	0 0%	3 27%	4 27%	1 ij100%	0 0%	4 h50%	2 15%	0 0%	2 15%	4 57%	1 17%	0 0%	0 0%	1 17%	6 38%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	16 100%	7 100%	0 100%	3 100%	11 100%	15 100%	1 100%	4 100%	8 100%	13 100%	0 100%	13 100%	7 100%	6 100%	0 100%	0 100%	6 100%	16 100%

How the treatment is being used by my peers in a clinical setting

	Total	A GP Principal	B Salaried GP	C GP Registrar	D Locum GP	E Male	F Female	G 1979 or earlier	H 1980-1989	I 1990-1999	J 2000-2010	K Under 30	L 30-39	M 40-49	N 50-59	O 60 or over	CCG gov board	CCG GP rep	CCG no active part
Ranked 1st	13 50%	8 50%	4 57%	0 0%	1 33%	5 45%	8 53%	0 0%	2 50%	5 g63%	6 g46%	0 0%	6 46%	4 57%	3 50%	0 0%	0 0%	2 33%	9 56%
Ranked 2nd	7 27%	5 b31%	0 0%	0 0%	2 b67%	3 27%	4 27%	1 hij100%	1 25%	1 13%	4 31%	0 0%	4 31%	1 14%	2 33%	0 0%	0 0%	4 67%	2 13%
Ranked 3rd	3 12%	1 6%	2 29%	0 0%	0 0%	1 9%	2 13%	0 0%	1 25%	2 25%	0 0%	0 0%	0 0%	2 29%	1 17%	0 0%	0 0%	0 0%	3 19%
Ranked 4th	1 4%	1 6%	0 0%	0 0%	0 0%	0 0%	1 7%	0 0%	0 0%	0 0%	1 8%	0 0%	1 8%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ranked 5th	2 8%	1 6%	1 14%	0 0%	0 0%	2 18%	0 0%	0 0%	0 0%	0 0%	2 15%	0 0%	2 15%	0 0%	0 0%	0 0%	0 0%	0 0%	2 13%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	16 100%	7 100%	0 100%	3 100%	11 100%	15 100%	1 100%	4 100%	8 100%	13 100%	0 100%	13 100%	7 100%	6 100%	0 100%	0 100%	6 100%	16 100%

What the adherence rates are in a clinical setting

	Total	A GP Principal	B Salaried GP	C GP Registrar	D Locum GP	E Male	F Female	G 1979 or earlier	H 1980-1989	I 1990-1999	J 2000-2010	K Under 30	L 30-39	M 40-49	N 50-59	O 60 or over	CCG gov board	CCG GP rep	CCG no active part
Ranked 1st	1 4%	1 6%	0 0%	0 0%	0 0%	0 0%	1 7%	0 0%	0 0%	0 0%	1 8%	0 0%	1 8%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ranked 2nd	4 15%	1 6%	2 29%	0 0%	1 33%	3 27%	1 7%	0 0%	1 25%	1 13%	2 15%	0 0%	2 15%	1 14%	1 17%	0 0%	0 0%	0 0%	3 19%
Ranked 3rd	10 38%	8 50%	1 14%	0 0%	1 33%	5 45%	5 33%	1 ij100%	2 50%	3 38%	4 31%	0 0%	4 31%	2 29%	4 67%	0 0%	0 0%	5 83%	5 31%
Ranked 4th	9 35%	4 25%	4 57%	0 0%	1 33%	3 27%	6 40%	0 0%	1 25%	3 38%	5 g38%	0 0%	5 38%	3 43%	1 17%	0 0%	0 0%	0 0%	7 44%
Ranked 5th	1 4%	1 6%	0 0%	0 0%	0 0%	0 0%	1 7%	0 0%	0 0%	0 0%	1 8%	0 0%	1 8%	0 0%	0 0%	0 0%	0 0%	0 0%	1 6%
Not ranked	1 4%	1 6%	0 0%	0 0%	0 0%	0 0%	1 7%	0 0%	0 0%	1 13%	0 0%	0 0%	0 0%	1 14%	0 0%	0 0%	0 0%	1 17%	0 0%
Total	26 100%	16 100%	7 100%	0 100%	3 100%	11 100%	15 100%	1 100%	4 100%	8 100%	13 100%	0 100%	13 100%	7 100%	6 100%	0 100%	0 100%	6 100%	16 100%

How to best fit the treatment into the current protocol, including when to switch patients

	Total	A GP Principal	B Salaried GP	C GP Registrar	D Locum GP	E Male	F Female	G 1979 or earlier	H 1980-1989	I 1990-1999	J 2000-2010	K Under 30	L 30-39	M 40-49	N 50-59	O 60 or over	CCG gov board	CCG GP rep	CCG no active part
Ranked 1st	6 23%	3 19%	3 43%	0 0%	0 0%	3 27%	3 20%	1 ij100%	0 0%	2 25%	3 23%	0 0%	3 23%	2 29%	1 17%	0 0%	0 0%	1 17%	5 31%
Ranked 2nd	4 15%	3 19%	1 14%	0 0%	0 0%	1 9%	3 20%	0 0%	1 25%	2 25%	1 8%	0 0%	1 8%	2 29%	1 17%	0 0%	0 0%	1 17%	3 19%
Ranked 3rd	7 27%	3 19%	2 29%	0 0%	2 67%	3 27%	4 27%	0 0%	1 25%	2 25%	4 g31%	0 0%	4 31%	2 29%	1 17%	0 0%	0 0%	0 0%	4 25%
Ranked 4th	5 19%	3 19%	1 14%	0 0%	1 33%	3 27%	2 13%	0 0%	2 50%	1 13%	2 15%	0 0%	2 15%	1 14%	2 33%	0 0%	0 0%	3 50%	2 13%
Ranked 5th	4 15%	4 bd25%	0 0%	0 0%	0 0%	1 9%	3 20%	0 0%	0 0%	1 13%	3 23%	0 0%	3 23%	0 0%	1 17%	0 0%	0 0%	1 17%	2 13%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	16 100%	7 100%	0 100%	3 100%	11 100%	15 100%	1 100%	4 100%	8 100%	13 100%	0 100%	13 100%	7 100%	6 100%	0 100%	0 100%	6 100%	16 100%

Absolutes/col percents

Table 17
Q3 Assuming that the real world evidence such as registry data or clinical audit has been peer reviewed, please rank the following information in order of how useful it would be in informing your prescribing practice?

Base: All respondents

	Total	D2 - Practice Location: Rural area (A)	Urban area (B)	Semi-rural area (C)	Suburban area (D)	Other (E)	D1 - Overall practice size: 1-2 (F)	3-5 (G)	6-10 (H)	11 or more (I)	D5 - Dispensing Practice: Yes (J)	No (K)	D7 - Number of patients on practice list: 1-2500 (L)	2501-5000 (M)	5001-7500 (N)	7501-10000 (O)	10001+ (P)
What the patient preference is for the treatment																	
Ranked 1st	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Ranked 2nd	6 23%	0 0%	5 acd50%	0 0%	1 8%	0 0%	1 25%	2 18%	3 33%	0 0%	1 33%	5 22%	1 50%	0 0%	2 33%	1 20%	2 33%
Ranked 3rd	4 15%	0 0%	1 10%	1 33%	2 17%	0 0%	0 0%	1 9%	2 22%	1 50%	1 33%	3 13%	0 0%	0 0%	2 33%	0 0%	2 33%
Ranked 4th	4 15%	0 0%	0 0%	2 20%	0 0%	2 17%	0 0%	0 0%	3 27%	1 11%	0 0%	4 j17%	0 0%	2 29%	0 0%	1 20%	1 17%
Ranked 5th	11 42%	1 bd100%	2 20%	2 67%	6 50%	0 0%	3 75%	4 36%	3 33%	1 50%	1 33%	10 43%	1 50%	5 np71%	1 17%	3 60%	1 17%
Not ranked	1 4%	0 0%	0 0%	0 0%	1 8%	0 0%	0 0%	1 9%	0 0%	0 0%	0 0%	1 4%	0 0%	0 0%	1 17%	0 0%	0 0%
Total	26 100%	1 100%	10 100%	3 100%	12 100%	0 100%	4 100%	11 100%	9 100%	2 100%	3 100%	23 100%	2 100%	7 100%	6 100%	5 100%	6 100%
That use in clinical settings validates the phase 3 trial data																	
Ranked 1st	6 23%	1 bd100%	2 20%	0 0%	3 25%	0 0%	3 gi75%	1 9%	2 22%	0 0%	0 0%	6 j26%	1 50%	2 29%	1 17%	2 40%	0 0%
Ranked 2nd	5 19%	0 0%	1 10%	3 bd100%	1 8%	0 0%	0 0%	4 fi36%	1 11%	0 0%	1 33%	4 17%	0 0%	3 p43%	1 17%	1 20%	0 0%
Ranked 3rd	2 8%	0 0%	1 10%	0 0%	1 8%	0 0%	0 0%	1 9%	1 11%	0 0%	0 0%	2 9%	0 0%	0 0%	1 17%	0 0%	1 17%
Ranked 4th	6 23%	0 0%	2 20%	0 0%	4 ac33%	0 0%	1 25%	0 0%	3 g33%	2 fh100%	1 33%	5 22%	1 50%	0 0%	0 0%	1 20%	4 mn67%
Ranked 5th	7 27%	0 0%	4 ac40%	0 0%	3 25%	0 0%	0 0%	5 fi45%	2 22%	0 0%	1 33%	6 26%	0 0%	2 29%	3 l50%	1 20%	1 17%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	1 100%	10 100%	3 100%	12 100%	0 100%	4 100%	11 100%	9 100%	2 100%	3 100%	23 100%	2 100%	7 100%	6 100%	5 100%	6 100%
How the treatment is being used by my peers in a clinical setting																	
Ranked 1st	13 50%	0 0%	5 a50%	2 67%	6 a50%	0 0%	1 25%	6 55%	5 56%	1 50%	2 67%	11 48%	1 50%	3 43%	4 67%	2 40%	3 50%
Ranked 2nd	7 27%	1 bd100%	3 30%	0 0%	3 25%	0 0%	3 gi75%	1 9%	3 33%	0 0%	0 0%	7 j30%	1 50%	2 29%	1 17%	2 40%	1 17%
Ranked 3rd	3 12%	0 0%	1 10%	0 0%	2 17%	0 0%	0 0%	3 27%	0 0%	0 0%	0 0%	3 13%	0 0%	1 14%	1 17%	1 20%	0 0%
Ranked 4th	1 4%	0 0%	0 0%	1 33%	0 0%	0 0%	0 0%	1 9%	0 0%	0 0%	0 0%	1 4%	0 0%	1 14%	0 0%	0 0%	0 0%
Ranked 5th	2 8%	0 0%	1 10%	0 0%	1 8%	0 0%	0 0%	0 0%	1 11%	1 50%	1 33%	1 4%	0 0%	0 0%	0 0%	0 0%	2 33%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	1 100%	10 100%	3 100%	12 100%	0 100%	4 100%	11 100%	9 100%	2 100%	3 100%	23 100%	2 100%	7 100%	6 100%	5 100%	6 100%
What the adherence rates are in a clinical setting																	
Ranked 1st	1 4%	0 0%	0 0%	1 33%	0 0%	0 0%	0 0%	1 9%	0 0%	0 0%	0 0%	1 4%	0 0%	1 14%	0 0%	0 0%	0 0%
Ranked 2nd	4 15%	0 0%	0 0%	0 0%	4 abc33%	0 0%	0 0%	1 9%	1 11%	2 gh100%	0 0%	4 j17%	0 0%	1 14%	0 0%	1 20%	2 33%
Ranked 3rd	10 38%	0 0%	6 a60%	1 33%	3 25%	0 0%	3 i75%	3 27%	4 i44%	0 0%	2 67%	8 35%	1 50%	3 43%	1 17%	3 60%	2 33%
Ranked 4th	9 35%	1 bd100%	4 40%	1 33%	3 25%	0 0%	1 25%	5 i45%	3 33%	0 0%	1 33%	8 35%	1 50%	2 29%	4 67%	1 20%	1 17%
Ranked 5th	1 4%	0 0%	0 0%	0 0%	1 8%	0 0%	0 0%	0 0%	1 11%	0 0%	0 0%	1 4%	0 0%	0 0%	0 0%	0 0%	1 17%
Not ranked	1 4%	0 0%	0 0%	0 0%	1 8%	0 0%	0 0%	1 9%	0 0%	0 0%	0 0%	1 4%	0 0%	0 0%	1 17%	0 0%	0 0%
Total	26 100%	1 100%	10 100%	3 100%	12 100%	0 100%	4 100%	11 100%	9 100%	2 100%	3 100%	23 100%	2 100%	7 100%	6 100%	5 100%	6 100%
How to best fit the treatment into the current protocol, including when to switch patients																	
Ranked 1st	6 23%	0 0%	3 30%	0 0%	3 25%	0 0%	0 0%	3 27%	2 22%	1 50%	1 33%	5 22%	0 0%	1 14%	1 17%	1 20%	3 l50%
Ranked 2nd	4 15%	0 0%	1 10%	0 0%	3 25%	0 0%	0 0%	3 27%	1 11%	0 0%	1 33%	3 13%	0 0%	1 14%	2 33%	0 0%	1 17%
Ranked 3rd	7 27%	1 bd100%	1 10%	1 33%	4 33%	0 0%	1 25%	3 27%	2 22%	1 50%	0 0%	7 j30%	1 50%	3 43%	1 17%	1 20%	1 17%
Ranked 4th	5 19%	0 0%	2 20%	1 33%	2 17%	0 0%	2 50%	1 9%	2 22%	0 0%	1 33%	4 17%	0 0%	2 29%	1 17%	2 40%	0 0%
Ranked 5th	4 15%	0 0%	3 30%	1 33%	0 0%	0 0%	1 25%	1 9%	2 22%	0 0%	0 0%	4 j17%	1 50%	0 0%	1 17%	1 20%	1 17%
Not ranked	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Total	26 100%	1 100%	10 100%	3 100%	12 100%	0 100%	4 100%	11 100%	9 100%	2 100%	3 100%	23 100%	2 100%	7 100%	6 100%	5 100%	6 100%